Challenges and threats
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Abstract Optimal breast cancer research requires collaboration between many stakeholders: scientists, clinicians, trialists, statisticians, the pharmaceutical industry, and most importantly patients and their representatives. The design of studies must be done more in accordance with patients’ needs and to optimize equity and diversity in access to innovation. Efforts should be made to design inclusive registration trials or generate evidence on unmet-need clinical settings such as subpopulations of ethnic/racial minorities, younger or older patients, male breast cancer patients, or patients with brain metastases. Patient-centred translational research is an important component of clinical trials. Selected endpoints should be clinically relevant endpoints and adapted to the disease setting and to the investigational therapeutic area. The current gap between innovation and clinical practice/use must be closed.
Fields of Study & Subjects
Breast Cancer Treatment Studies
Statistical Methods in Clinical Trials
Ethics in Clinical Research
Publication details
- Journal / source
- Oxford University Press eBooks
- Pages
- 320–326
- Publication date
- 1 March 2026
- Language
- EN
- Document type
- Book chapter